Advances towards COVID-19
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 7868 792050

Advances towards COVID-19

An epidemic of viral pneumonia, most probably caused by novel coronavirus, has emerged in Wuhan, China, 2020. The causative agent was identified very swiftly during the course of the epidemic, but epidemiological situations have dynamically changed over time: initially, many cases were considered to have been linked to an exposure at a seafood market in Wuhan, but a massive number of cases have started to emerge not only in Wuhan city but across different cities in China and also in other well connected countries.

Many unknown characteristics of this disease remain. What kind of people is mainly affected? How does the clinical spectrum of this disease look like? Are transmissions from human to human taking place in the community and also in households? How long does it take from exposure to illness onset? How transmissible is the disease? When is the infectiousness highest during the course of infection? How severe is the infection, and what kind of people with underlying characteristics are particularly at high risk of death? To respond to the outbreak in a timely manner, it is vital that research responses to the outbreak focusing on above mentioned subjects are published in our Journal of Clinical Trials in a timely manner. This Special Issue will act as a publication media to attract many clinical and epidemiological studies on this outbreak, ensuring a fast turnaround time for high quality studies.

We particularly welcome articles providing new insights into

(i) Advances towards COVID19

Potential topics include but are not limited to the following:

This Special Issues will cover original articles and review articles related to novel coronavirus COVID-19 clinical trials, antimicrobial resistance, social aspects and economic burden of disease, laboratory identification, community interventions, GIS application, and mathematical models. Topics include but not limited to;

Clinical trials, Global burden, Disability-adjusted life years (DALY), Risk factors, Community interventions, Laboratory studies, Drug resistance, GIS applications, Cost-effective analysis, Vaccine, Mathematical models, Social epidemiology, Modeling & environmental epidemiology, Extreme Weather, Seasonality, Environmental Monitoring, Disease Tracking, Surveillance Systems, Public Health and Environmental Policies.

We welcome both solicited and unsolicited submissions that will contribute to this goal.

There will be two modes of manuscript submission. The authors can directly submit their manuscript through e-mail at or through our online submission system at: